<DOC>
	<DOCNO>NCT02214628</DOCNO>
	<brief_summary>The objective evaluate safety intravitreal Fovista® ( anti-PDGF BB ) administer combination anti-VEGF therapy</brief_summary>
	<brief_title>Phase 2A Open Label Safety Study Fovista® ( Anti-PDGF BB ) Regimen Administered Combination With Anti-VEGF Therapy Study Sub-Retinal Fibrosis Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Subjects either gender age ≥ 50 year All flourescein angiographic subtypes presence active choroidal neovascularization Any intraocular surgery thermal laser within three ( 3 ) month trial entry . Any prior thermal laser macular region , regardless indication Subjects subfoveal scar subfoveal atrophy Any ocular periocular infection past twelve ( 12 ) week History follow condition procedure study eye : Rhegmatogenous retinal detachment , par plana vitrectomy , filter surgery ( e.g . trabeculectomy ) , glaucoma drainage device , corneal transplant</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Wet AMD</keyword>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Fovista®</keyword>
	<keyword>E10030</keyword>
	<keyword>Avastin®</keyword>
	<keyword>Eylea®</keyword>
</DOC>